2025年美国糖尿病协会(ada)第85届科学会议报告

SummaryThe American Diabetes Association (ADA) 85th Scientific Sessions was held in Chicago, Illinois from June 20-June 23, 2025 and featured the latest data from current therapeutic interventions and drug candidates for type1 and type 2 diabetes, and obesity.Key data presented included the latest results of numerous glucagon-likepeptide 1 (GLP-1)-based therapies for type II diabetes and obesity.This post-meeting report features commentary from our analysts on specific presentations. It also includes acompilation of data events added in conjunction with the meeting.AbouttheAuthorBiomedtrackeris anindependent research service that offers proprietary clinical assessments and patient-basedrevenue forecasts of developmental drugs within a comprehensive and intuitive drug information database. Clientsfrom the pharmaceutical, biotech, and investment industries rely on Biomedtracker forits insight on the likelihood ofapproval, commercialpotential,andfuturedataandregulatorycatalystsfordrugswithinthecompetitivelandscapeofevery important disease and indication. Over the last several years, Biomedtracker has become the leader inproviding objective information alongside evidence based clinical assessments and investment research on pipelinedrugs worldwide. For more information on getting direct access to Biomedtracker, please emailclientservices@evaluate.com.DisclaimerCopyright©2025Evaluate,aNorstellacompanyThis report is published by Evaluate (thePublisher). This report contains information from reputable sources andalthough reasonable efforts have been made to publish accurate information, you assume sole responsibility for theselection, suitabilityanduseof thisreportandacknowledgethat thePublishermakesnowarranties(either expressorimplied) as to, nor accepts liabilityfor, the accuracy or fitness for a particular purpose of the information or advicecontained herein. The Publisher wishes to make it clear that anyviews or opinions expressed in this report byindividual authors or contributors are their personal views and opinions and do not necessarily reflect theviews/opinions of the Publisher. Copyright©2025 Evaluate,aNorstella company (Unauthorized photocopying prohibited) Table of ContentsBGM0504FORDIABETESMELLITUS,TYPEII………...……………………………………………………………..4MAZDUTIDE FORDIABETESMELLITUS,TYPEII………..……………………………………………………………..7BMF-219FORDIABETESMELLITUS,TYPEII………….……………………………………………….…….……...10HRS-7535FORDIABETESMELLITUS,TYPEII…..……….………………………………………...………………..13ORFORGLIPRON FORDIABETESMELLITUS,TYPEII…………………………………………………………………..16GZR18FORDIABETESMELLITUS,TYPEII……………...……………………………………….............................20GZR18FORDIABETESMELLITUS,TYPEII…………………………………………………………………………...22HRS-7535FOROBESITY………………………………..………………………………………………..………….24KAI-9531FOROBESITY………..………………………………………………………………...…………………..26RGT-075FOROBESITY…………………...………………………………………………………….…………….29BGM0504FOROBESITY……………..……………………………………….…………………………………….31WEGOVY FOROBESITY……………………….………………………………………...........................................33BIOGLUTIDE FOROBESITY..………………………………………………………………………...........................36NN9490FOROBESITY...……………………………………………...................................................................38LIST OFBIOMEDTRACKERADAEVENTS..…………………………………………..………………………………..41 Copyright © 2025 Evaluate, a Norstella company (Unauthorized photocopying prohibited) BGM0504 for Diabetes Mellitus, Type IIEvent Date:06/23/2025Event Type:Trial Data - Top-Line Results (Clinical Analysis)Trial Name:Phase II - BGM0504-IIa-T2DMMarket Group:EndocrineLead Company:BrightGene Bio-Medical Technology Co., Ltd. (688166)Partner Companies:N/AFormer Companies:N/AChange to Likelihood of Approval:0%Likelihood of Approval:0% (Same As Avg.)Average Approval:N/ATreatmentTreatmentTreatment DescriptionBGM0504(5mg)BGM0504(10mg)Number of Patients1312Number of Evaluable PatientsN/AN/AReductions in HbA1c at Week12(Endpoint=Primary)-1.72 %-1.94 %BrightGene Pharmaceutical announced that data from Phase II study of BGM0504 was presented in an oral presentation entitled"Efficacy and Safety of BGM0504 in Chinese Patients with Type 2 Diabetes—A Multicenter, Randomized, Double-Blind,Placebo-Controlled and Semaglutide Positive-Controlled Phase 2 Trial" at the American Diabetes Association (ADA) on June 23,2025.DesignThis multicenter, randomized, double-blind (placebo-controlled) and open-label (semaglutide positive-controlled) enrolled 67participants with type 2 diabetes between the ages of 18 and 65, 64 received dose after randomization, randomized into five groups:5mg (n=13), 10mg (n=12), 15mg (n=13), positive-control group (semaglutide; n=16) or placebo (n=13). Enrolled participants includedadults with a baseline HbA1c between 7.0% and 10.0%, and a body mass index (BMI) between 19.5 and 35 kg/m 2.EndpointsPharmacokinetics, safety and efficacy of once-weekly subcutaneous injection of BGM0504 across the primary endpoint, change fromCopyright © 2025 Evaluate, a Norstella company (Unauthorized photocopying